

Food and Drug Administration FY 2024 Operating Plan Narrative

Overview: On March 09, 2024, the President signed the Consolidated Appropriations Act, 2024 (P.L. 118-42). The FY 2024 appropriation provides a total program level of \$6.9 billion to FDA, which is an increase of \$151.7 million above the FY 2023 Enacted Level. This total includes \$3.6 billion in budget authority, which is a decrease of \$15.8 million below FY 2023. This also includes \$3.3 billion for user fees and \$50.0 million of 21st Century Cures funding.

Changes Compared to FY 2023 Enacted:

Infrastructure – reduction of \$7.788 million to FDA’s Buildings and Facilities:

- -\$7.8 million for Buildings and Facilities.

Headquarters – reduction of \$8.0 million to FDA Headquarters:

- -\$8.0 million to Headquarters.

Reallocations – The Committee reduced FDA BA levels for certain programs by \$8.5 million and reallocated those funds to support:

Crosscutting – net neutral reallocation for Crosscutting activities:

- -\$1.5 million reduction across budget authority accounts.
- +\$1.5 million for Reducing Animal Testing Through Alternative Methods.

Cosmetics – net neutral reallocation for the following activity:

- -\$7.0 million reduction across budget authority accounts.
- +\$7.0 million for Modernization of Cosmetics Regulation Act of 2022 (MoCRA) Implementation.